Amarin Corp Plcuk (AMRN) Total Current Liabilities (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Total Current Liabilities of $179.6 million for Q1 2026, up 10.61% YoY from $162.4 million in Q1 2025, and down 7.62% sequentially from $194.5 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Total Current Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Total Current Liabilities across 17 years of filings, most recently posting $179.6 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 10.61% year-over-year to $179.6 million; the TTM figure through Mar 2026 stood at $179.6 million (up 10.61% YoY), while the FY2025 annual figure was $194.5 million, up 8.06% from the prior year.
- Total Current Liabilities fell to $179.6 million in Q1 2026, from $194.5 million in the prior quarter.
- Over the last five years, Total Current Liabilities for AMRN reached as high as $361.6 million in Q2 2022 and fell as low as $162.4 million in Q1 2025.
- The 5-year median for Total Current Liabilities is $230.5 million (2024), against an average of $234.8 million.
- Annual changes were most pronounced in 2024 — Total Current Liabilities tumbled 30.6% — and 2026, when it gained 10.61%.
- A 5-year view of Total Current Liabilities shows it stood at $259.5 million in 2022, then slipped by 0.08% to $259.3 million in 2023, then plunged by 30.6% to $179.9 million in 2024, then increased by 8.06% to $194.5 million in 2025, then decreased by 7.62% to $179.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $179.6 million, $194.5 million, and $182.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 36.63 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 57.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 42.10 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -32.57 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 179.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 179.64 Mn |
| Dec 31, 2025 | 194.46 Mn |
| Sep 30, 2025 | 182.23 Mn |
| Jun 30, 2025 | 185.95 Mn |
| Mar 31, 2025 | 162.41 Mn |
| Dec 31, 2024 | 179.95 Mn |
| Sep 30, 2024 | 201.55 Mn |
| Jun 30, 2024 | 230.54 Mn |
| Mar 31, 2024 | 224.38 Mn |
| Dec 31, 2023 | 259.28 Mn |
| Sep 30, 2023 | 266.69 Mn |
| Jun 30, 2023 | 270.93 Mn |
| Mar 31, 2023 | 244.24 Mn |
| Dec 31, 2022 | 259.48 Mn |
| Sep 30, 2022 | 287.36 Mn |
| Jun 30, 2022 | 361.57 Mn |
| Mar 31, 2022 | 300.57 Mn |
| Dec 31, 2021 | 370.68 Mn |
| Sep 30, 2021 | 364.75 Mn |
| Jun 30, 2021 | 370.44 Mn |